Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes

Journal of Diabetes Investigation

Volumn 5, Issue 3, 2014, Pages 327-332

  Esteghamati, Alireza ^a   Ghasemiesfe, Mehrnaz ^a   Mousavizadeh, Mostafa ^a   Noshad, Sina ^a   Nakhjavani, Manouchehr ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chemerin; Metformin; Pioglitazone

Indexed keywords

CHEMERIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; BODY WEIGHT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOCRINE PANCREAS FUNCTION TEST; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84899935175     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12157     Document Type: Article

References (29)

1. Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006; 14(Suppl. 5): 242S-249S.
2. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556.
3. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: S64-S73.
4. Zabel BA, Allen SJ, Kulig P, et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005; 280: 34661-34666.
5. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148: 4687-4694.
6. Verrijn Stuart AA, Schipper HS, Tasdelen I, et al. Altered plasma adipokine levels and in vitro adipocyte differentiation in pediatric type 1 diabetes. J Clin Endocrinol Metab 2012; 97: 463-472.
7. El-Mesallamy HO, El-Derany MO, Hamdy NM. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med 2011; 28: 1194-1200.
8. Hu W, Yu Q, Zhang J, et al. Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats. Inflammation 2012; 35: 1287-1293.
9. Lin X, Tang X, Jiang Q, et al. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with type 2 diabetes. Clin Lab 2012; 58: 539-544.
10. Yoo HJ, Choi HY, Yang SJ, et al. Circulating chemerin level is independently correlated with arterial stiffness. J Atheroscler Thromb 2012; 19: 59-66.
11. Vernochet C, Peres SB, Davis KE, et al. C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. Mol Cell Biol 2009; 29: 4714-4728.
12. Tan BK, Chen J, Farhatullah S, et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009; 58: 1971-1977.
13. Pei L, Yang J, Du J, et al. Downregulation of chemerin and alleviation of endoplasmic reticulum stress by metformin in adipose tissue of rats. Diabetes Res Clin Pract 2012; 97: 267-275.
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011; 34(Suppl. 1): S62-S69.
15. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
16. Bondue B, Wittamer V, Parmentier M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev 2011; 22: 331-338.
17. Sell H, Laurencikiene J, Taube A, et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009; 58: 2731-2740.
18. Roh S, Song SH, Choi KC, et al. Chemerin-a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 2007; 362: 1013-1018.
19. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003; 198: 977.
20. Bozaoglu K, Segal D, Shields KA, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 2009; 94: 3085-3088.
21. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
22. Farmer SR. Transcriptional control of adipocyte formation. Cell Metab 2006; 4: 263-273.
23. Hofmann C, Lorenz K, Colca JR. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 1991; 129: 1915-1925.
24. Fukui Y, Masui S, Osada S, et al. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes 2000; 49: 759-767.
25. Wilson-Fritch L, Burkart A, Bell G, et al. Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol Cell Biol 2003; 23: 1085-1094.
26. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-461.
27. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137-1140.
28. Kralisch S, Weise S, Sommer G, et al. Interleukin-1fl induces the novel adipokine chemerin in adipocytes in vitro. Regul Pept 2009; 154: 102-106.
29. Kloting N, Fasshauer M, Dietrich A, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010; 299: E506-E515.